Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease arising from complications related to lung injury during the treatment of infant acute respiratory distress syndrome in low-birth-weight premature infants, or from abnormal lung development in older infants. The condition is recognized by Orphanet, GARD (NIH), and the MONDO Ontology. No known causative genes are recorded in this packet; BPD is understood as a multifactorial condition influenced by prematurity, oxygen exposure, and mechanical ventilation rather than single-gene etiology. Inheritance pattern data are not applicable to this condition based on the packet contents.

Per the definition in this packet, clinical signs of bronchopulmonary dysplasia include tachypnea, tachycardia, and signs of respiratory distress such as intercostal recession, grunting, and nasal flaring. Phenotype-level HPO terms are not available in this packet (total_phenotype_count = 0), and no additional symptom data are certified in this packet beyond the definition-level clinical description above.

This packet records no known causative genes for bronchopulmonary dysplasia. The definition in this packet attributes the condition to lung injury during treatment of infant acute respiratory distress syndrome in low-birth-weight premature infants, or to abnormal lung development. No inheritance pattern, onset category, or genetic etiology data are certified in this packet. The research landscape digest (375 classified publications, dominant type: Basic Science/Preclinical) indicates active preclinical investigation into the pathophysiology of BPD.

Diagnostic criteria and methods are not certified in this packet. BPD is recognized by Orphanet (Orphanet ID 70589) and GARD (NIH). No diagnostic method or laboratory findings are specified in the packet beyond the clinical definition citing tachypnea, tachycardia, and respiratory distress signs.

No FDA-approved treatments are listed in this packet for bronchopulmonary dysplasia. This packet records 19 orphan drug designations; designation status does not indicate FDA approval or confirmed efficacy, and no designated agent carries an ACTIVE market_status in this packet. No approved treatment data are available to describe in this section.

Natural history data are not certified in this packet. Prognosis characterization beyond the general description of BPD as a chronic respiratory condition is not available within the bounds of this packet.

The research landscape digest for bronchopulmonary dysplasia covers 375 classified publications, with a dominant research type of Basic Science/Preclinical, 85 reviews, and 5 case reports, per internal Kisho classification. ClinicalTrials.gov records 68 active trials indexed to this condition. Active recruiting studies include an inhaled ciclesonide study in preterm infants (NCT06589245, RECRUITING per ClinicalTrials.gov) and a study on pulmonary hypertension and oxygen saturation targeting in preterm infants (NCT06373289, RECRUITING per ClinicalTrials.gov). The research landscape digest indicates representation across gene therapy and biomarker research areas.